Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

Bibliography

• Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Goldman-Levine JD. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011;31:44S-53S
   PubMed Web of Science ®Google Scholar
• Sibal L, Home PD. Management of type 2 diabetes: NICE guidelines. Clin Med 2009;9:353-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Paschos P, Paletas K, Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
   PubMed Web of Science ®Google Scholar
• Consoli A, Gomis R, Halimi S, Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026
   PubMed Web of Science ®Google Scholar
• Diamant M. Choosing a blood-glucose-lowering agent after metformin. Lancet 2012;379:2220-1
   PubMed Web of Science ®Google Scholar
• Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther 2011;33:408-24
   PubMed Web of Science ®Google Scholar
• Morgan CL, Poole CD, Evans M, What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4605-12
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• Liu SC, Tu YK, Chien MN, Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012;14:810-20
   PubMed Web of Science ®Google Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-42
   PubMed Web of Science ®Google Scholar
• Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 2007;154:19-28
   PubMedGoogle Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents - an update. Drug Saf 2005;28:601-31
   PubMed Web of Science ®Google Scholar
• Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008;13:593-607
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Controversy about the relative efficacy of DPP-4 inhibitors. Diabetologia 2012;55:2848-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012;380:450-2
   PubMed Web of Science ®Google Scholar
• Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 2012;23:132-6
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012;23:126-31
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
   PubMed Web of Science ®Google Scholar
• Bosi E, Dotta F, Jia Y, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15
   PubMed Web of Science ®Google Scholar
• Guarino E, Nigi L, Patti A, Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:1377-84
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
   PubMed Web of Science ®Google Scholar
• Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs 2011;71:349-61
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother 2012;13:139-46
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
   PubMed Web of Science ®Google Scholar
• Howlett H, Porte F, Allavoine T, The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003;19:218-25
   PubMed Web of Science ®Google Scholar
• Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2009;10:1091-104
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611-24
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Setter SM. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther 2012;34:993-1005
   PubMed Web of Science ®Google Scholar
• Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2012;72:1793-824
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Friedrich C, Port A, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
   PubMed Web of Science ®Google Scholar
• Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-44
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• Barnett AH, Patel S, Harper R, Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 2012; published on line 2012/09/15; doi: 10.1111/dom.12011
   Web of Science ®Google Scholar
• Owens DR, Swallow R, Dugi KA, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-61
   PubMed Web of Science ®Google Scholar
• Aronson R. Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. Expert Opin Pharmacother 2012;13:1535-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012;8:383-94
   PubMed Web of Science ®Google Scholar
• Jentadueto, INN-linagliptin/metformin HCl. CHMP assessment report. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002279/WC500130972.pdf [Last accessed 05 November 2012]
   Google Scholar
• Jentadueto (linagliptin plus metformin). Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201281s000lbl.pdf [Last accessed 06 November 2012]
   Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
   PubMed Web of Science ®Google Scholar
• Sambol NC, Brookes LG, Chiang J, Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996;42:510-12
   Google Scholar
• Sambol NC, Chiang J, Lin ET, Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995;35:1094-102
   PubMed Web of Science ®Google Scholar
• Gong L, Goswami S, Giacomini KM, Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012;22:820-7
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-15
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
   PubMedGoogle Scholar
• Takane H, Shikata E, Otsubo K, Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9:415-22
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012;33:312-22
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Shimizu H, Kishimoto W, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos 2013;41:149-58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51:411-27
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Hüttner S, Graefe-Mody EU, Withopf B, Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8
   PubMed Web of Science ®Google Scholar
• Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78
   PubMed Web of Science ®Google Scholar
• Retlich S, Duval V, Graefe-Mody U, Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010;50:873-85
   PubMed Web of Science ®Google Scholar
• Retlich S, Duval V, Ring A, Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010;49:829-40
   PubMed Web of Science ®Google Scholar
• Wright S, Singh RP, Retlich S, The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety. Int J Clin Pharmacol Ther 2012;50:323-30
   PubMed Web of Science ®Google Scholar
• Sarashina A, Sesoko S, Nakashima M, Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010;32:1188-204
   PubMed Web of Science ®Google Scholar
• Friedrich C, Shi X, Zeng P, Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2012;50:889-95
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Giessmann T, Ring A, A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011;33:1096-103
   PubMed Web of Science ®Google Scholar
• Heise T, Graefe-Mody EU, Hüttner S, Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-94
   PubMed Web of Science ®Google Scholar
• Horie Y, Kanada S, Watada H, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 2011;33:973-89
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU, Padula S, Ring A, Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Haring HU, Matthaei S. Metformin. Endocr Res 2007;32:39-57
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70
   PubMed Web of Science ®Google Scholar
• Mannucci E, Ognibene A, Cremasco F, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94
   PubMed Web of Science ®Google Scholar
• Mannucci E, Tesi F, Bardini G, Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004;17:336-42
   PubMedGoogle Scholar
• Thondam SK, Cross A, Cuthbertson DJ, Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 2012;29:e205-10
   PubMed Web of Science ®Google Scholar
• Hinke SA, Kuhn-Wache K, Hoffmann T, Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291:1302-8
   PubMed Web of Science ®Google Scholar
• Cuthbertson J, Patterson S, O'Harte FP, Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med 2009;26:649-54
   PubMed Web of Science ®Google Scholar
• Mulherin AJ, Oh AH, Kim H, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152:4610-19
   PubMed Web of Science ®Google Scholar
• Kappe C, Patrone C, Holst JJ, Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol 2012; published on line 2012/08/02; doi: 10.1007/s00535-012-0637-5
   PubMed Web of Science ®Google Scholar
• Migoya EM, Miller J, Larsson P, Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations (Abstract). Diabetes 2007;56:A74
   Web of Science ®Google Scholar
• Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4:383-94
   PubMedGoogle Scholar
• Rauch T, Graefe-Mody U, Deacon CF, Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10- doi; 10.1007/s13300-012-0010-y
   PubMedGoogle Scholar
• Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2012;14:694-708
   PubMed Web of Science ®Google Scholar
• Rendell M, Chrysant SG. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgrad Med 2011;123:183-6
   PubMed Web of Science ®Google Scholar
• Forst T, Uhlig-Laske B, Ring A, Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409-19
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
   PubMed Web of Science ®Google Scholar
• Ross SA, Rafeiro E, Meinicke T, Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28:1464-75
   Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Rosenstock J, Rauch T, 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-83
   PubMed Web of Science ®Google Scholar
• Haak T, Meinicke T, Jones R, Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565-74
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Emser A, Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470-8
   PubMed Web of Science ®Google Scholar
• Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33:1609-29
   PubMed Web of Science ®Google Scholar
• Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; published on line 2012/04/24; doi: 10.1111/j.1463-1326.2012.01610.x
   Google Scholar
• Gomis R, Owens DR, Taskinen MR, Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract 2012;66:731-40
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; In press
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE, Rationale and design of the CAROLINA trial: an active comparator CARdiovascular Outcome study of the DPP-4 Inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Diabetes 2011;60(Suppl 1; Poster: 1103-P (71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24 – 28, 2011):A303
   Google Scholar
• Lamanna C, Monami M, Marchionni N, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, von Eynatten M, Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3
   PubMed Web of Science ®Google Scholar
• McGill JB, Sloan L, Newman J, Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2012; published on line 2012/10/04; doi: 10.2337/dc12-0706
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Efficacy and safety of jentadueto (linagliptin plus metformin). Expert Opin Drug Saf 2013. In press
   Web of Science ®Google Scholar